COVID-19
Conditions
Keywords
COVID-19, vaccine, influenza vector
Brief summary
The aim of the study is to investigate the safety and immunogenicity of a two-component intranasal vaccine for the prevention of COVID-19 in healthy volunteers 18-60 years old
Detailed description
Study include three parts. During the first part the two vaccine components will be administered separately to a small number of seronegative participants in low dose and then high dose to evaluate each component's safety. During the second part vaccine components would be administered one after another with 21 days interval to evaluate safety of the complete vaccine regimen (low dose and high dose). During the third part of the study the high dose vaccine will be administered to participants to evaluate vaccine immunogenicity. The whole study will include 200 participants. Duration of the study for each participant is about 6.5 months (no more than 194 days).
Interventions
BIOLOGICALCorfluvec component 1 low dose
Participants will receive single intranasal injection of H3N2 recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2
BIOLOGICALCorfluvec component 2 low dose
Participants will receive single intranasal injection of H1N1pdm09 recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2
BIOLOGICALCorfluvec component 1 high dose
Participants will receive single intranasal injection of H3N2 recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2
BIOLOGICALCorfluvec component 2 high dose
Participants will receive single intranasal injection of H1N1pdm09 recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2
BIOLOGICALCorfluvec low dose
Participants will receive two intranasal injections of recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2 tree weeks apart (H3N2 →H1N1pdm09)
BIOLOGICALCorfluvec high dose
Participants will receive two intranasal injections of recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2 tree weeks apart (H3N2 →H1N1pdm09)
BIOLOGICALPlacebo
Participants will receive two intranasal injections of placebo three weeks apart
Sponsors
MDP-CRO, LLC
St. Petersburg State Pavlov Medical University
Tatyana Zubkova
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
1. Availability of signed informed consent 2. Adult men and women aged 18-60 3. Diagnosed healthy according to the data of standard clinical, laboratory and instrumental examination methods, with the absence of clinically significant changes 4. Body Mass Index (BMI): 18.5≤ BMI ≤30 kg/m2 5. HI antibody titers ≤1:20 to influenza A/H1N1pdm09 and A/H3N2 (only for phase 1) 6. Serum antibodies to the SARS-CoV-2 N-protein not higher than 100 BAU/ml 7. The ability and willingness to make entries in the diary of self-observation, as well as to carry out all the visits foreseen in the study for control medical observation 8. Negative test for alcohol in exhaled air 9. Consent to use effective contraceptive methods throughout their participation in the study 10. Values of the complete blood count and biochemical blood analysis (during the screening) within 0.9\*reference range lower limit and 1,1 \* reference range upper limit 11. Negative tests for HIV, hepatitis B, hepatitis C, and syphilis
Exclusion criteria
1. Contact with COVID-19 patients within 14 days prior to the start of the clinical study 2. Positive rapid test result for SARS-CoV-2 antigen 3. Participation in another clinical study within three months prior to the start of the current study; planning to participate in another study during the current study period. 4. Immunization with any other non-study vaccine product, including COVID-19 vaccination within four weeks prior to enrollment in the current study, or refusal to postpone such until the end of the four-week period after completion of the current study 5. Regular use of nasal irrigation therapy during the last six months prior to enrollment in the current study or episodic use of the above method of treatment in the two weeks prior to the screening 6. History of frequent nosebleeds (\>5) during the year prior to the current study 7. Clinically significant anatomic pathology or the presence of surgical intervention in the sinus area, paranasal sinuses, or traumatic injuries of the nose within a month before screening 8. Symptoms of acute respiratory disease, including fever, or other acute illness at the time of screening or within two weeks prior to screening 9. Treatment with immunoglobulins or other blood derived medications in the three months prior to screening or planning such treatment during the period of participation in the current study; donation of blood/plasma (450 ml or more) less than 2 months prior to screening 10. The presence or suspicion of the presence of various immunosuppressive or immunodeficiency conditions or continuous use (the drug was prescribed for more than 14 days without a break) of immunosuppressive drugs, immunomodulators for 6 months before the screening 11. History of bronchial asthma 12. Hypersensitivity and the presence of severe allergic reactions, including Quincke's edema, anaphylactic shock after the previous administration of any vaccine 13. History of wheezing after previous immunization with live influenza vaccine 14. Other adverse events after immunization (fever above 40°C, syncope, non-febrile convulsions, anaphylaxis) when there is a minimal likelihood that they are associated with a previous administration of any vaccine 15. Suspicion of hypersensitivity to any component of the study vaccine, including egg protein 16. Seasonal (in spring or autumn) increased sensitivity to the effects of natural factors 17. Acute or chronic clinically significant lung, cardiovascular, hepatic, endocrine, neurological, or psychiatric disorders, or impaired renal function identified by history, physical examination, or clinical laboratory findings that, in the opinion of the investigator, may influence the outcome of the study 18. History of leukemia or any other malignant diseases of the blood or solid malignant neoplasms of other organs 19. History of thrombocytopenic purpura or bleeding disorders 20. History of convulsions 21. The presence or suspicion of the presence of various immunosuppressive or immunodeficiency conditions, including HIV infection 22. Tuberculosis or residual changes after tuberculosis according to the anamnesis and / or available medical documentation 23. Chronic alcohol dependence or chronic use of illicit drugs, drug abuse 24. Claustrophobia and social phobia according to history and / or available medical records 25. For women of reproductive age - lactation, pregnancy or suspected pregnancy, early postpartum period 26. Premenopausal women (last menstrual period \<1 year prior to signing informed consent) who are not surgically sterile and women who are of reproductive potential but do not use or plan to use valid birth control throughout the study and do not agree to perform a urine pregnancy test while participating in the study 27. Military personnel undergoing military service on conscription 28. Persons in custody in pre-trial detention centers and serving sentences in places of deprivation of liberty 29. Special diet (eg, vegetarian, vegan, salt-restricted) or lifestyle (night work, extreme physical activity) 30. Any condition that, in the opinion of the investigator, may increase the risk to the health of a volunteer participating in the study or affect the results of the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Level of SARS-CoV-2 antigen specific mucosal and systemic IgA and IgG antibody | Throughout the 42±2 study days | Change from baseline in the levels of IgA and IgG antibody to SARS-CoV-2 N protein measured in ELISA in saliva/nasal secret and serum |
| Number of participants with local and systemic adverse events (AEs) and serious adverse events (SAEs) | Throughout the study, average of 6.5 months | Number of participants with AEs and SAEs including those of particular interest: * immediate AEs (allergic reactions) occurring within 2 h after vaccination; * post-vaccination reactions between 2 h and a subsequent 7 days; * other AEs including unexpected clinical manifestations of a local and systemic nature occurring on the day of vaccination and the following 7 days; * deviations of laboratory parameters of analyzes of blood and urine samples and data from instrumental studies (ECG) obtained on Days 3, 7, 23 and 27; * all SAEs occurring up to 3 weeks after each vaccination; late AEs occurring after study Day 42 through Day 180±5; * influenza A virus shedding detected by rapid test in nasal swab samples |
| Level of SARS-CoV-2 antigen specific cytokine release in whole blood assay | Throughout the 42±2 study days | Change from baseline in the cytokine concentration in whole-blood cytokine release assay upon in vitro stimulation with SARS-CoV-2 N protein peptide epitopes |
| Level of SARS-CoV-2 antigen specific cytokine producing T-cells | Throughout the 42±2 study days | Change from baseline in the level of cytokine producing T-cells upon in vitro stimulation of PBMC with SARS-CoV-2 N protein peptide epitopes measured by ICS/ELISPOT |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Seroconversion rate of SARS-CoV-2 antigen specific antibody | Days 21, 42±2 | Proportion of participants who have at least a 4-fold increase in post-vaccination antibody titers in comparison to baseline |
| Number of responders to vaccination according to the fold increase in the level of specific T-cell response | Days 7, 21, 27, 42±2 | Proportion of participants exhibiting significant increase in the level of specific T-cell response to SARS-CoV-2 N protein after vaccination in comparison to baseline. The increase in the parameter is considered significant if it exceeds the specified range, which is a 95% CI for mean value of parameter fold change in the Placebo group at assessment day compared to Day 1 |
Other
| Measure | Time frame | Description |
|---|---|---|
| Concentration of cytokines in nasal secrets after vaccination | Throughout the first 48h of the study | Change from the baseline in the concentration of cytokines in nasal secrets measured in ELISA/Multiplex system |
| Efficacy against symptomatic COVID-19 and influenza | Throughout the study, average of 6.5 months | Number of laboratory-confirmed symptomatic cases of COVID-19 and influenza |
| SARS-CoV-2 and influenza specific antibody and T-cell immune response (follow-up) | Days 90±3, 180±5 | Specific systemic antibody and T-cell immune response to SARS-CoV-2 N protein and influenza viruses (A/H1N1pdm09, A/H3N2) measured in ELISA, ISC/ELISPOT, whole-blood cytokine release assay. |
| Influenza specific local and systemic antibody immune response | Throughout the 42±2 study days | Change from baseline in the uiters of influenza specific antibodies in serum and saliva/nasal secret measured in ELISA, HI, MNA and corresponding seroconversion rates. |
Countries
Russia
Outcome results
None listed